DE69836740D1 - Amyloid beta protein (globularer aufbau und seine verwendung) - Google Patents

Amyloid beta protein (globularer aufbau und seine verwendung)

Info

Publication number
DE69836740D1
DE69836740D1 DE69836740T DE69836740T DE69836740D1 DE 69836740 D1 DE69836740 D1 DE 69836740D1 DE 69836740 T DE69836740 T DE 69836740T DE 69836740 T DE69836740 T DE 69836740T DE 69836740 D1 DE69836740 D1 DE 69836740D1
Authority
DE
Germany
Prior art keywords
addls
activity
formation
globular
amyloid beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69836740T
Other languages
English (en)
Other versions
DE69836740T2 (de
Inventor
A Krafft
L Klein
A Chromy
P Lambert
E Finch
Todd Morgan
Pat Wals
Irina Rozovsky
Ann Barlow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwestern University
University of Southern California USC
Original Assignee
Northwestern University
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwestern University, University of Southern California USC filed Critical Northwestern University
Publication of DE69836740D1 publication Critical patent/DE69836740D1/de
Application granted granted Critical
Publication of DE69836740T2 publication Critical patent/DE69836740T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69836740T 1997-02-05 1998-02-05 Amyloid beta protein (globulärer aufbau und seine verwendung) Expired - Lifetime DE69836740T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US796089 1997-02-05
US08/796,089 US6218506B1 (en) 1997-02-05 1997-02-05 Amyloid β protein (globular assembly and uses thereof)
PCT/US1998/002426 WO1998033815A1 (en) 1997-02-05 1998-02-05 Amyloid beta protein (globular assembly and uses thereof)

Publications (2)

Publication Number Publication Date
DE69836740D1 true DE69836740D1 (de) 2007-02-08
DE69836740T2 DE69836740T2 (de) 2007-10-11

Family

ID=25167266

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69836740T Expired - Lifetime DE69836740T2 (de) 1997-02-05 1998-02-05 Amyloid beta protein (globulärer aufbau und seine verwendung)

Country Status (12)

Country Link
US (2) US6218506B1 (de)
EP (2) EP0998495B1 (de)
JP (2) JP3512815B2 (de)
AT (1) ATE349467T1 (de)
AU (1) AU735825B2 (de)
BR (1) BR9807185A (de)
CA (1) CA2279555C (de)
DE (1) DE69836740T2 (de)
DK (1) DK0998495T3 (de)
ES (1) ES2280090T3 (de)
PT (1) PT998495E (de)
WO (1) WO1998033815A1 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US20030068316A1 (en) * 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US20060178302A1 (en) * 1997-02-05 2006-08-10 Northwestern University & The University Of Southern California Amyloid beta protein (globular assembly and uses thereof)
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
EP1187920A2 (de) 1999-06-09 2002-03-20 Arch Development Corporation Rekombinante prionänhliche gene, proteine, materialien und verfahren davon
DE60043165D1 (de) 1999-08-04 2009-11-26 Univ Southern California Globularer Aufbau vom Amyloid-beta- protein und deren Verwendungen
EP1240525A2 (de) 1999-12-23 2002-09-18 PHARMACIA & UPJOHN COMPANY Natriumkanalen als ziele für amyloid beta
TR200202799T3 (tr) * 2000-02-24 2003-03-21 Washington University St.Louis AB peptidini sekanslayan insanlaştırılmış antikorlar
CA2414772C (en) * 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US6815175B2 (en) * 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
DK1944040T3 (da) * 2001-08-17 2012-10-29 Univ Washington Analysefremgangsmåde for Alzheimers sygdom
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2004031400A2 (en) * 2002-10-01 2004-04-15 Northwestern University Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR20050118669A (ko) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 ａ-베타에 대한 항체를 생성하기 위한 능동 면역화
ATE468886T1 (de) 2003-02-10 2010-06-15 Applied Molecular Evolution Abeta-bindende moleküle
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US8250823B2 (en) 2003-08-26 2012-08-28 Ejot Gmbh & Co. Kg Dowels and methods for the assembly of insulating panels
US20080306074A1 (en) * 2004-05-14 2008-12-11 Lacor Pascale N Compositions Comprising Addl Receptors, Related Compositions, and Related Methods
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
US20080044356A1 (en) * 2004-10-22 2008-02-21 Regents Of The University Of Minnesota Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof
WO2006055178A2 (en) * 2004-10-25 2006-05-26 Merck & Co., Inc. Anti-addl antibodies and uses thereof
TW200635607A (en) * 2004-12-15 2006-10-16 Elan Pharm Inc Humanized Aβ antibodies for use in improving cognition
PE20061401A1 (es) * 2004-12-15 2006-12-23 Neuralab Ltd ANTICUERPOS Aß PARA MEJORAR LA COGNICION
TW200636066A (en) * 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
US7731962B2 (en) * 2005-02-14 2010-06-08 Merck & Co., Inc. Anti-ADDL monoclonal antibody and use thereof
US8420093B2 (en) 2005-02-14 2013-04-16 Merck Sharp & Dohme Corp. Anti-ADDL monoclonal antibody and use thereof
JP4937143B2 (ja) * 2005-03-05 2012-05-23 アボット ゲーエムベーハー ウント カンパニー カーゲー 非拡散性球状Ａβ（Ｘ−３８．．４３）オリゴマー構造エピトープに対して特異性を有する自己抗体を検出する方法
AU2006222193B2 (en) 2005-03-05 2011-11-17 AbbVie Deutschland GmbH & Co. KG Screening method, process for purifying of non-diffusible A-beta oligomers, selective antibodies against said non-diffusible A-beta oligomers and a process for manufacturing of said antibodies
DE102005014936A1 (de) 2005-03-24 2006-12-14 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
CA2617104A1 (en) * 2005-07-29 2007-02-08 Regents Of The University Of Minnesota Amyloid beta receptor and uses thereof
US20080014596A1 (en) * 2005-11-16 2008-01-17 Jasna Jerecic ADDL Binding to Hippocampal Neurons
WO2007064917A2 (en) 2005-11-30 2007-06-07 Abbott Laboratories Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
AU2006319358B2 (en) * 2005-11-30 2012-01-19 AbbVie Deutschland GmbH & Co. KG Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
KR101439828B1 (ko) 2005-11-30 2014-09-17 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
RU2015111675A (ru) * 2005-12-12 2015-08-10 Ац Иммуне Са Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами
RU2429244C2 (ru) * 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
JP4876224B2 (ja) * 2006-06-05 2012-02-15 財団法人ヒューマンサイエンス振興財団 アミロイドβオリゴマー並びにその製造方法及び使用方法
KR101605207B1 (ko) * 2006-07-14 2016-03-22 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
EP1882944B1 (de) * 2006-07-28 2009-03-18 VISTA VENTURES GmbH Verfahren zum Nachweis der amyloid-beta Oligomere in Körperflüssigkeiten
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
PT2842967T (pt) * 2007-01-18 2017-01-13 Lilly Co Eli Fab beta amilóide peguilado
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
RU2523894C2 (ru) * 2007-04-18 2014-07-27 Янссен Альцгеймер Иммунотерапи Предупреждение и лечение церебральной амилоидной ангиопатии
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
CN101820911B (zh) * 2007-06-12 2015-05-06 Ac免疫有限公司 β淀粉样蛋白的人源化抗体
MX2010000368A (es) 2007-07-12 2010-07-02 Acumen Pharmaceuticals Inc Metodos para modificar los oligomeros beta-amiloides usando compuestos no peptidicos.
US8962677B2 (en) * 2007-07-12 2015-02-24 Acumen Pharmaceuticals, Inc. Methods of restoring cognitive ability using non-peptidic compounds
US20110098309A1 (en) * 2007-07-12 2011-04-28 Acumen Pharmaceuticals, Inc. Methods of inhibiting the formation of amyloid-beta diffusable ligands using acylhydrazide compounds
US9006283B2 (en) * 2007-07-12 2015-04-14 Acumen Pharmaceuticals, Inc. Methods of modifying amyloid β oligomers using non-peptidic compounds
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
EP2238166B1 (de) * 2007-10-05 2013-11-27 Genentech, Inc. Verwendung eines anti-amyloid-beta-antikörpers bei augenkrankheiten
US8932558B2 (en) * 2007-10-05 2015-01-13 Plaxgen Inc Multi-subunit biological complexes for treatment of plaque-associated diseases
RU2542967C2 (ru) * 2007-10-05 2015-02-27 Дженентек, Инк. Применение антитела против амилоида бета при глазных заболеваниях
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CA2702880A1 (en) * 2007-10-19 2009-04-23 Immunas Pharma, Inc. Antibody capable of specifically binding to a beta oligomer, and use thereof
US20100291071A1 (en) * 2008-08-01 2010-11-18 Immunas Pharma, Inc. Antibody Specific Binding to A-Beta Oligomer and the Use
US8993714B2 (en) * 2007-10-26 2015-03-31 Imiplex Llc Streptavidin macromolecular adaptor and complexes thereof
US9217024B2 (en) 2007-12-18 2015-12-22 Acumen Pharmaceuticals, Inc. ADDL receptor polypeptides, polynucleotides and host cells for recombinant production
PL2246427T3 (pl) 2008-02-08 2017-06-30 Immunas Pharma, Inc. Przeciwciała zdolne do wiązania się swoiście do oligomerów amyloidu beta i ich stosowanie
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
US9102526B2 (en) 2008-08-12 2015-08-11 Imiplex Llc Node polypeptides for nanostructure assembly
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
ES2641612T3 (es) 2009-04-17 2017-11-10 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a oligómeros de beta A y uso de los mismos
WO2010132363A1 (en) 2009-05-11 2010-11-18 Imiplex Llc Method of protein nanostructure fabrication
EP2462161B1 (de) 2009-08-06 2017-03-08 Immunas Pharma, Inc. Spezifisch an abeta-oligmomere bindende antikörper und ihre verwendung
US8613924B2 (en) 2009-08-06 2013-12-24 Immunas Pharma, Inc. Antibodies that specifically bind to A beta oligomers and use thereof
CA2769464C (en) 2009-08-07 2017-11-21 Kyowa Hakko Kirin Co., Ltd. Humanized anti-amyloid-.beta. oligomer antibody
WO2011016568A1 (ja) 2009-08-07 2011-02-10 協和発酵キリン株式会社 抗アミロイドβオリゴマーヒト化抗体
EP2368558A1 (de) 2010-03-23 2011-09-28 Mdc Max-Delbrück-Centrum Für Molekulare Medizin Berlin - Buch Azoverbindungen zur Reduzierung der Bildung und der Toxizität von Amyloid-Beta-Aggregationszwischenprodukten
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
DK2593475T3 (en) 2010-07-14 2016-05-30 Merck Sharp & Dohme Anti-ADDL monoclonal antibody and uses thereof
US9176151B2 (en) 2010-07-14 2015-11-03 Acumen Pharmaceuticals, Inc. Antibodies, kit and method for detecting amyloid beta oligomers
SG187173A1 (en) 2010-07-30 2013-02-28 Ac Immune Sa Safe and functional humanized anti beta-amyloid antibody
EP3533803B1 (de) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antikörper
MX2014000480A (es) 2011-07-13 2014-06-23 Merck Sharp & Dohme Metodo para la deteccion de oligomeros beta amiloide en una muestra de fluidos y usos de los mismos.
US9377472B2 (en) 2012-04-30 2016-06-28 Amoneta Diagnostics Biological complex specific for Alzheimer's disease detection in vitro and use thereof
EP4023294A1 (de) 2014-01-31 2022-07-06 Cognition Therapeutics, Inc. Isoindolinzusammensetzungen und verfahren zur behandlung der alzheimer-krankheit
KR20230129449A (ko) 2014-07-10 2023-09-08 바이오악틱 에이비 개선된 Aβ 프로토피브릴 결합 항체
WO2024071361A1 (ja) * 2022-09-27 2024-04-04 株式会社カネカ 凝集性タンパク質に対する凝集抑制活性又は凝集促進活性を評価する方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE247282T1 (de) 1992-10-26 2003-08-15 Elan Pharm Inc Verfahren zur identifizierung von hemmstoffe der produktion des beta-amyloidpeptids
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)

Also Published As

Publication number Publication date
WO1998033815A1 (en) 1998-08-06
DK0998495T3 (da) 2007-05-07
JP2004091492A (ja) 2004-03-25
US6218506B1 (en) 2001-04-17
PT998495E (pt) 2007-03-30
ATE349467T1 (de) 2007-01-15
EP0998495B1 (de) 2006-12-27
US20060166275A1 (en) 2006-07-27
JP3512815B2 (ja) 2004-03-31
EP0998495A1 (de) 2000-05-10
US7638283B2 (en) 2009-12-29
EP1808444A1 (de) 2007-07-18
DE69836740T2 (de) 2007-10-11
AU6273598A (en) 1998-08-25
ES2280090T3 (es) 2007-09-01
AU735825B2 (en) 2001-07-19
CA2279555A1 (en) 1998-08-06
BR9807185A (pt) 2000-01-25
JP2001501972A (ja) 2001-02-13
CA2279555C (en) 2012-05-01

Similar Documents

Publication Publication Date Title
DE69836740D1 (de) Amyloid beta protein (globularer aufbau und seine verwendung)
DE60016227D1 (de) Globularer aufbau vom amyloid-beta- protein und deren verwendungen
WO2004031400A3 (en) Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof
DE69635740D1 (de) Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen
ATE466883T1 (de) Katalytische monoklonale antikörper mit proteaseaktivität zur selektiven lysis der proteinkomponente von mit pathologischen konditionen zusammenhängenden plaques und aggregaten
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
ATE485303T1 (de) Isoformen von gehirn-natriuretischem peptid
NO976094L (no) Nye peptider avledet av humant varmesjokkprotein 60 for behandling av diabetes, fremgangsmåte og sett
DE69840752D1 (de) Verwendung von coumarine zur behandlung von lebererkrankungen und pankreaserkrankungen
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
DE59806627D1 (de) Arylsulfonamide und analoga und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
ATE499445T1 (de) Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b
DE68909465T2 (de) Behandlung von Pferdeviehbestand.
DE69837148D1 (de) Chimäre proteine zur behandlung von diabetes
DE69910425D1 (de) Neue therapeutische verwendung von nicergoline
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
DE69809223T2 (de) 5-alpha-pregnan-3-beta-ol-20-one 3-sulfate für di behandlung von tumoren und zns krankheiten
DE69408394T2 (de) 4-Piperidino-piperidin zur Behandlung von Tumoren
DE68908445D1 (de) Mittel zur behandlung von lebererkrankungen.
DE69910608D1 (de) Neue therapeutische verwendung von 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin
DE58903550D1 (de) Mittel zur behandlung von chronisch entzuendlichen darmerkrankungen.
ATE542900T1 (de) Icbp90-polypeptide, polypeptidfragmente davon, die dafür kodierenden polynukleotide, und ihre verwendung zur behandlung und diagnose von krebs
ATE95036T1 (de) Behandlung von pferdeviehbestand.
DE3765250D1 (de) Verwendung von 24,25-dihydroxycholecalciferol zur behandlung von harnsteinen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition